Illumina

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Trade Illumina 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About ILMN

Illumina, Inc. engages in the development, manufacturing, and marketing of life science tools and integrated systems for large-scale analysis of genetic variation and function. The company was founded by David R. 

CEO
Jacob Thaysen
CEOJacob Thaysen
Employees
8,600
Employees8,600
Headquarters
San Diego, California
HeadquartersSan Diego, California
Founded
1998
Founded1998
Employees
8,600
Employees8,600

ILMN Key Statistics

Market cap
42.01B
Market cap42.01B
Price-Earnings ratio
51.84
Price-Earnings ratio51.84
Dividend yield
—
Dividend yield—
Average volume
2.96M
Average volume2.96M
High today
$279.10
High today$279.10
Low today
$265.25
Low today$265.25
Open price
$268.21
Open price$268.21
Volume
1.90M
Volume1.90M
52 Week high
$309.35
52 Week high$309.35
52 Week low
$88.00
52 Week low$88.00

Stock Snapshot

Illumina(ILMN) stock is priced at $278.00, giving the company a market capitalization of 42.01B. It carries a P/E multiple of 51.84.

On 2026-10-10, Illumina(ILMN) stock moved within a range of $265.25 to $279.10. With shares now at $278.00, the stock is trading +4.8% above its intraday low and -0.4% below the session's peak.

Trading activity shows a volume of 1.9M, compared to an average daily volume of 2.96M.

Over the past 52 weeks, Illumina(ILMN) stock has traded between a high of $309.35 and a low of $88.00.

Over the past 52 weeks, Illumina(ILMN) stock has traded between a high of $309.35 and a low of $88.00.

ILMN News

TipRanks 1d
Illumina price target raised to $168 from $140 at BofA

BofA raised the firm’s price target on Illumina (ILMN) to $168 from $140 and keeps an Underperform rating on the shares. The life science tools sector has furth...

Simply Wall St 2d
Illumina Gains On Clinical And AI Optimism, Is It Fully Priced?

Illumina (ILMN) is back in focus after recent analyst research highlighted expectations for stronger clinical sales and framed its gene sequencing platforms as...

Illumina Gains On Clinical And AI Optimism, Is It Fully Priced?

Analyst ratings

46%

of 24 ratings
Buy
45.8%
Hold
37.5%
Sell
16.7%

People also own

Based on the portfolios of people who own ILMN. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.